Patents by Inventor Marc R Morra

Marc R Morra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200339672
    Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.
    Type: Application
    Filed: July 10, 2020
    Publication date: October 29, 2020
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Lynn MACDONALD, Richard TORRES, Marc R. MORRA, Joel H. MARTIN, Joel C. REINHARDT, Paul TISEO
  • Patent number: 10745471
    Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: August 18, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
  • Patent number: 10513557
    Abstract: The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: December 24, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Min Gao, Marc R. Morra, Nicole M. Alessandri-Haber, Michael L. LaCroix-Fralish
  • Publication number: 20190211090
    Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.
    Type: Application
    Filed: February 21, 2019
    Publication date: July 11, 2019
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Lynn MACDONALD, Richard TORRES, Marc R. MORRA, Joel H. MARTIN, Joel C. REINHARDT, Paul TISEO
  • Patent number: 10266588
    Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: April 23, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
  • Publication number: 20180222976
    Abstract: The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders.
    Type: Application
    Filed: September 28, 2017
    Publication date: August 9, 2018
    Inventors: Lynn MacDonald, Min Gao, Marc R. Morra, Nicole M. Alessandri-Haber, Michael L. LaCroix-Fralish
  • Publication number: 20160237148
    Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.
    Type: Application
    Filed: May 2, 2016
    Publication date: August 18, 2016
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Lynn MACDONALD, Richard TORRES, Marc R. MORRA, Joel H. MARTIN, Joel C. REINHARDT, Paul TISEO
  • Patent number: 9371383
    Abstract: The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. According to certain embodiments, the antibodies of the invention are selective for ASIC1 and do not bind other acid-sensing ion channels in the absence of ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: June 21, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Min Gao, Marc R. Morra, Nicole M. Alessandri-Haber, Michael L. LaCroix-Fralish
  • Patent number: 9353176
    Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: May 31, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
  • Publication number: 20160002332
    Abstract: The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders.
    Type: Application
    Filed: September 9, 2015
    Publication date: January 7, 2016
    Inventors: Lynn MacDonald, Min Gao, Marc R. Morra, Nicole M. Alessandri-Haber, Michael L. LaCroix-Fralish
  • Patent number: 9150648
    Abstract: The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: October 6, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Min Gao, Marc R. Morra, Nicole M. Alessandri-Haber, Michael L. LaCroix-Fralish
  • Patent number: 9028819
    Abstract: The present invention provides antibodies that bind to protease-activated receptor-2 (PAR-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PAR-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more PAR-2 biological activities, including the treatment of pain conditions, inflammatory conditions and gastrointestinal conditions.
    Type: Grant
    Filed: March 26, 2013
    Date of Patent: May 12, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Andrew J. Murphy, Nicholas J. Papadopoulos, Marc R. Morra, Robert R. Salzler, Michael L. LaCroix-Fralish
  • Publication number: 20140220023
    Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.
    Type: Application
    Filed: September 26, 2013
    Publication date: August 7, 2014
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: LYNN MACDONALD, RICHARD TORRES, MARC R. MORRA, JOEL H. MARTIN, JOEL C. REINHARDT, PAUL TISEO
  • Publication number: 20140056907
    Abstract: The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. According to certain embodiments, the antibodies of the invention are selective for ASIC1 and do not bind other acid-sensing ion channels in the absence of ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders.
    Type: Application
    Filed: October 31, 2013
    Publication date: February 27, 2014
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Lynn MACDONALD, Min GAO, Marc R. MORRA, Nicole M. ALESSANDRI-HABER, Michael L. LaCROIX-FRALISH
  • Patent number: 8637031
    Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: January 28, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
  • Patent number: 8613927
    Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: December 24, 2013
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt
  • Patent number: 8425907
    Abstract: The present invention provides methods for treating pruritus by blocking human protease activated receptor-2 (PAR2) activity. The methods of the invention can be used to treat pruritus associated with atopic dermatitis, psoriasis, burn scarring, hypertrophic scarring, keloids, renal failure or hepatic failure. The methods of the invention include administering an antibody or antigen-binding fragment thereof that specifically binds human PAR2.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: April 23, 2013
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Andrew J. Murphy, Nicholas J. Papadopoulos, Marc R. Morra, Robert R. Salzler, Michael L. LaCroix-Fralish
  • Patent number: 8309088
    Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: November 13, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
  • Publication number: 20120164688
    Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.
    Type: Application
    Filed: February 28, 2012
    Publication date: June 28, 2012
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MACDONALD, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt
  • Publication number: 20120093824
    Abstract: The present invention provides methods for treating pruritus by blocking human protease activated receptor-2 (PAR2) activity. The methods of the invention can be used to treat pruritus associated with atopic dermatitis, psoriasis, burn scarring, hypertrophic scarring, keloids, renal failure or hepatic failure. The methods of the invention include administering an antibody or antigen-binding fragment thereof that specifically binds human PAR2.
    Type: Application
    Filed: December 14, 2011
    Publication date: April 19, 2012
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MACDONALD, Andrew J. MURPHY, Nicholas J. PAPADOPOULOS, Marc R. MORRA, Robert R. SALZLER, Michael L. LACROIX-FRALISH